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ABSTRACT 
Background: Autoantibodies (Aabs) are the hallmark of numerous systemic autoimmune pathologies (SAPs), for 
instance anti-Ro/SS-A Aabs are usually found in Systemic Lupus Erythematosus (SLE) and Sjögren’s Syndrome. 
Cutaneous photosensitivity (CP) is found in most forms and subsets of LE and consists of a skin rash as a result 
of unusual reaction to sunlight. There are many theories which relate specifically the presence of circulating anti- 
Ro/SS-A Aabs with the CP phenomenon, though there are several studies which are in disagreement. Results: In 
this study we analyzed the relationship between CP and anti-Ro Aabs by means of two approaches. The first 
one included an in vitro model where we evaluated by flow cytometry the binding capacity of affinity-purified 
Aabs to autoantigens relocalized on apoptotic keratinocyte’s surface. We found that there was no relationship 
between the binding capacity of serum from 10 selected patients or their corresponding purified anti-Ro52 and 
anti-Ro60 Aabs, and the presence or absence of CP, neither with the SAPs. The in vivo model consisted of Hair-
less SKH:1 mice which were induced to produce anti-murine Ro52 and/or Ro60 Aabs and were subsequently 
irradiated with UVB light. We evaluated the skin histology and also the epidermal production of TNF-α. We 
found no differences between the groups in neither of the parameters evaluated. Conclusions: These results 
agree with some studies on the role of the Aabs in CP, considering anti-Ro Aabs not as the only responsible for 
the manifestation; and disagree with many other authors, who believe in the strong association between these 
two events. 
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1. Introduction 
Exposure to sunlight has long been associated with ex- 
acerbation of Systemic Lupus Erythematosus (SLE), not 
only of cutaneous manifestations like photosensitivity, 
but also of several disease symptoms such as weakness, 
fatigue and joint pain [1]. Up to 90% of patients with 
SLE report cutaneous photosensitivity (CP), which—ac- 
cording to the American College of Rheumatology— 
consists of a skin rash as a result of unusual reaction to 
sunlight, by patient history or physician observation [2-3].  
CP is found in most forms and subsets of Lupus Erythe- 
matosus (LE) like Subacute Cutaneous (SCLE), Neonatal 
(NLE), Discoid (DLE) and SLE, and also in patients with 
Dermatomyositis [4-6]. The main responsible for the 
harmful effects of sunlight is ultraviolet radiation 
(UVr)—specially UVB (280 - 320 nm), though it has 
also been demonstrated that UVA (320 - 400 nm) can 
contribute to the induction of LE skin lesions [7].  
Autoantibodies (Aabs) are the hallmark of numerous 
systemic autoimmune pathologies (SAPs). These Aabs  
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have many nuclear targets, like proteins (Sm, histones, 
etc.) DNA and ribonucleoprotein complexes (RNPs) such 
as the RoRNP, among others. This complex is composed 
by a RNA molecule and three proteins: La/SS-B of 47 
kDa located in the nucleus, Ro/SS-A of 52 kDa and 
Ro/SS-A of 60 kDa, which can be found in the nucleus 
and also free in the cytoplasm [8]. The incidence of an- 
ti-Ro/SS-A Aabs is different according to the SAP in- 
volved: in primary Sjögren’s Syndrome (pSS) and sec- 
ondary SS (sSS) is about 80% - 95% and in SLE these 
Aabs appear in 30% - 60% of all cases [9-11]. Although 
anti-Ro/SS-A 52 kDa and anti-Ro/SS-A 60 kDa Aabs are 
usually evaluated together as anti-Ro/SS-A, it is useful to 
detect them separately because each of them have dif- 
ferent connotations. For instance, it has been proven that 
anti-Ro/SS-A 52 kDa Aabs are responsible for the pa- 
thogenesis of congenital heart block [12] and it has been 
reported that anti-Ro/SS-A 60 kDa Aabs are associated 
with glandular dysfunction in SS patients [13]. Addition-
ally, anti-Ro/SS-A 60 kDa Aabs have recently been iden-
tified as an early marker which can occur years before 
SLE disease onset and have been proposed as an initiat-
ing target that promotes epitope spreading to additional 
autoantigenic specificities [14]. 
Apoptosis is an active process that leads to the ordered 
removal of living cells avoiding the generation of an in- 
flammatory environment. This is desirable in most of the 
cases, though in SAPs this might not be so favorable. It 
has been demonstrated that UVr driven apoptotic kerati- 
nocytes relocate RNPs towards the cell membrane [15,16] 
and this event could, on a first instance, induce the pro- 
duction of Aabs [17]. Subsequently these circulating 
Aabs could bind to the apoptotic keratinocytes’ mem- 
brane, producing Aabs mediated cytotoxicity, finally 
leading to an unwanted inflammatory response, which 
under normal conditions would not take place [18]. 
These events are proposed to be relevant in the genera- 
tion of cutaneous damage in SAPs patients. 
It stands to reason why anti-Ro/SS-A Aabs have tradi- 
tionally been associated with the CP phenomenon [19- 
21]. Nevertheless, there are some facts which are in dis-
agreement with the previous statement. To begin with, 
there are epidemiological data which indicate that there 
is not a significant direct association between anti-Ro/ 
SS-A Aabs and CP [22-24]; moreover there is the fact 
that 75% of pSS’s patients do have anti-Ro/SS-A Aabs, 
many with high Aabs titers, but not CP [25,26]; further- 
more there is the occurrence of CP in individuals that do 
not show any kind of disease, neither any circulating 
Aabs [27]. Anyhow, beyond all this controversy the ac- 
tual mechanism which triggers CP has not been fully 
elucidated yet, though the relationship between CP and 
anti-Ro/SS-A Aabs has been studied focusing on differ- 
ent aspects. These include the expression of autoantigens 
in the skin [28], the presence of certain Aabs [21] and 
also the relation with apoptotic cell death induced by 
UVr [29], but the study of the above mentioned associa- 
tion using purified anti-Ro/SS-A Aabs has been poorly 
explored. 
The study of this association in an animal model is al- 
so vacant, though some approaches have been made, 
such as the study of the deposition of immunoglobulins 
in human skin-grafted mice [30] and the induction of 
erythema in animals with passive transferred Aabs [31] 
However, these studies do not include the analysis of 
skin inflammatory mediators—such as TNF-α—which 
has been related to the pathogenesis of photosensitive 
lupus. This relation is based on studies of human TNF-α 
polymorphisms in lupus patients and measures of their 
cytokine serum levels [32] Nonetheless, there has been 
contradictory data about this matter, since TNF-α block-
ing agents are able to induce lupus-like syndromes, in-
cluding skin disease [4,33]. 
In this study we analyzed the relationship between CP 
and anti-Ro/SS-A Aabs by means of two approaches. 
The first one includes an in vitro model where we eva- 
luated the binding capacity of purified Aabs to apoptotic 
keratinocyte’s cell surface by flow cytometry. We se- 
lected 10 patients from a previous larger study, according 
to their clinical characteristics and laboratory findings, 
and affinity-purified anti-Ro/SS-A of 52 kDa and anti- 
Ro/SS-A of 60 kDa Aabs from their serum samples. We 
analyzed the existence of a relationship between the 
binding profile to apoptotic keratinocytes of the serum 
and pure Aabs of each patient, and the presence or ab- 
sence of CP. The in vivo model consists of Hairless 
SKH:1 mice which were induced to produce anti-murine 
Ro/SS-A 52 and/or Ro/SS-A 60 Aabs and were subse- 
quently irradiated with UVB light. We evaluated the skin 
histology and also the epidermal production of TNF-α. 
2. Materials and Methods 
2.1. Ethics Statement 
Serum samples from patients and healthy volunteers 
were obtained from the Rheumatology Service of the 
Hospital de Clínicas José de San Martín, Buenos Aires, 
Argentina. All studies were conducted, and all samples 
were obtained with written, informed consent under In- 
stitutional Review Board on Human Ethics approved 
protocols from the mentioned Hospital. The study has 
been performed in accordance with the ethical standards 
laid down in the 1964 World Medical Association Dec- 
laration of Helsinki. 
Animals were used in compliance with the research 
animal use guidelines established by the Consejo Na- 
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cional de Investigaciones Científicas y Técnicas (CON- 
ICET-Argentina) and with the EC Directive 86/609/EEC 
[34]. The protocol was approved by the Institutional Re- 
view Board on Ethics of Animal Experiments of the In- 
stituto de Estudios de la Inmunidad Humoral (IDEHU) 
from CONICET-University of Buenos Aires. 
2.2. Patients, Samples and Controls 
A cohort of 169 individuals were examined at the Rheu- 
matology Service of the Hospital de Clínicas José de San 
Martín, as part of a previous larger study [24], then 10 of 
those patients were selected for this study, according to 
their clinical characteristics and laboratory findings. Di- 
agnoses of SLE, SS, Rheumatoid Arthritis (RA) and CP 
were made according to the criteria adopted in the ab- 
ovementioned previous study.  
Twenty milliliters (ml) of serum were obtained from 
each of the 10 patients and stored at –20˚C until the puri- 
fication processes began. Sera from 10 healthy subjects 
(normal human serum, NHS) were used as control; 1 ml 
of each one was pooled and stored at –20˚C. All 10 NHS 
obtained were tested individually for ANA, anti-Ro/SS-A 
52 and anti-Ro/SS-A 60 kDa, being the results always 
negative. Immunoglobulin G (IgG) concentration was 
measured in sera from the 10 patients and also in the 
NHS pool by radial immunodiffusion (Diffu-Plate, Bio- 
científica, Argentina). 
2.3. Affinity Purification of Aabs against  
Recombinant Ro/SS-A 52 kDa and Ro/SS-A  
60 
Recombinant human Ro/SS-A 52 kDa and Ro/SS-A 60 
kDa (Ro52 and Ro60 hereafter) were cloned and ex- 
pressed in an E-coli system, where a N-terminal 6× His- 
tidine-tag was added to the proteins and then they were 
purified using an immobilized metal ion adsorption 
chromatography, as described before [24]. Aabs against 
either Ro52 or Ro60 proteins were isolated from sera by 
affinity chromatography, using the corresponding re- 
combinant protein coupled to CNBr-activated Sepharose 
4B (GE Healthcare, Little Chalfont, Buckinghamshire, 
United Kingdom) according to the manufacturer’s in- 
structions. Briefly, 1 ml of CNBr-activated resin was 
mixed with 2 ml of protein (1 mg/ml) for 2 h at room 
temperature using an end-over-end mixer; next unreacted 
groups were blocked with Glycine 0.2 M pH 8, for 2 h at 
room temperature and finally the resin was washed with 
phosphate buffered saline (PBS). Afterwards, 2 ml of 
patient’s serum were allowed to recirculate through the 
affinity column for 1 h, in order for the specific Aabs to 
bind to their antigen. Washing steps were performed first 
with PBS, then with PBS-NaCl 0.5 M. Anti-Ro52 or an- 
ti-Ro60 Aabs were eluted with Glycine 0.1 M pH 3.5 and 
then pH 2.7, using an ÄKTA purifier system (GE 
Healthcare). Eluted fractions (1 ml each) were imme- 
diately neutralized with 1 M Tris-HCl pH 8 and subse- 
quently tested for anti-Ro reactivity by a heterogeneous 
non-competitive ELISA, coated with the recombinant 
proteins, as described before [24]. High reactivity frac- 
tions were pooled (one pool for fractions eluted at pH 3.5 
and another for 2.7) and dialyzed against PBS. Pooled 
fractions were titrated by ELISA and their protein con- 
centration determined by BCA Protein Assay Kit (Pierce, 
Rockford, IL, USA) using the extended protocol sug- 
gested by the manufacturer, in order to increase the sen- 
sitivity of the detection. Finally they were stored at 
–80˚C in glycerol 10% until the flow cytometric analysis 
began.  
Reactivity against native Ro proteins was also eva- 
luated for the pooled fractions, using an indirect immu- 
nofluorescence technique with commercially available 
Hep-2 cells (Kallestad, BIORAD, Houston, TX, USA), 
according to the manufacturers’ instructions. 
2.4. In Vitro Model 
A human keratinocyte cell line, HaCaT, was kindly pro- 
vided by Dr N. E. Fusenig (German Cancer Research 
Center, Heidelberg, Germany) [35]. HaCaT cells were 
cultured in plastic dishes and subconfluent cells were 
irradiated with 50 mJ/cm2 of UVB light as previously 
described [36,37] in order to obtain a high percentage of 
apoptotic cells. At least one dish was not exposed to 
UVB irradiation, but was handled in the same fashion as 
the irradiated cells, that is to say the culture medium was 
replaced by PBS before the irradiation. After irradiation, 
the PBS was immediately replaced with DMEM. All 
detached and attached cells were harvested and collected 
24 h after UVB irradiation and they were incubated with 
PBS-total rabbit serum 1/10, for 2 h at 4˚C before the 
labeling for flow cytometry, to block Fc receptors in or- 
der to prevent unspecific binding of Igs. 
Aabs binding to cell surface was measured by flow 
cytometry, incubating total irradiated cells (1 × 106 cells) 
with patients’ sera or affinity-purified anti-Ro52 or anti- 
Ro60 Aabs for 2 h at 4˚C, followed by rapid fixation 
with p-formaldehyde 2%. Using this method, binding to 
cell surface is allowed and subsequent internalization of 
Aabs is prevented. Sera were used at a dilution of 1:100 
in PBS-1% BSA and purified Aabs were assayed undi- 
luted. This was done in order to make the anti-Ro reac- 
tivity equivalent both in sera and purified Aabs for every 
patient. NHS (1:100), human purified IgG (hIgG, 0.1 
mg/ml) and secondary antibody alone (UBC—unspecific 
binding control) were used as controls. Sera and NHS 
IgG masses used were equal, hIgG control was used in a 
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concentration equivalent to one of the purified Aabs frac- 
tion which presented the highest mass. After washing 
twice with cold PBS, cells were incubated with second- 
ary antibody FITC-conjugated goat anti-human IgG H + 
L (Bethyl, Montgomery, TX, USA) at a dilution of 1:100 
in PBS-1% BSA, for 2 h at room temperature. After the 
final washing with PBS cells were analyzed with a 
PAS-III PARTEC flow cytometer (Münster, Germany). 
In each experiment, the same first antibody labeling (sera, 
purified Aabs, NHS and hIgG) was also performed on 
non-irradiated cells. 
2.5. In Vivo Model 
In vivo assays were performed using male and female Crl: 
SKH-1-hrBR Hairless mice of 8 weeks of age, purchased 
from Charles River Laboratories. Animals were housed 
in quarters with 12/12 h light/dark cycle and maintained 
with water and food ad libitum.  
Mice were divided into 4 groups of 10 animals, and a 
conventional intraperitoneal immunization schedule was 
performed with 100 µg of each protein in complete 
Freund’s adyuvant (CFA). Immunizations (total of 6) 
were made in 20-day intervals and sample taking (total of 
3) in 40-day intervals. Groups were immunized with re- 
combinant human Ro52 (Group 1), recombinant human 
Ro60 (Group 2), recombinant human Ro52 and Ro60 
(Group 3), and the vehicle buffer in CFA (Group 4). 
Blood samples were taken by facial vein puncture and 
tested for reactivity against recombinant human Ro pro- 
teins by ELISA, as described before [24], and also 
against mice spleen extract in order to test autoreactivity 
[38]. 
When the animals’ anti-Ro autoreactivity values be- 
came different from the control (group 4) in a statistically 
significant way, each group was divided in two, one 
group was irradiated (5 mice) and the other was mocked- 
irradiated (5 mice). They were irradiated on their back 
with one minimal erythema dose (200 mJ/cm2) of UVB, 
as described before [36]. After irradiation, animals were 
kept in the same conditions for 24 h and they were sub- 
sequently sacrificed. Non-irradiated mice were used as 
control and they were handled in the same fashion as the 
irradiated animals. Mice were sacrificed using a CO2 gas 
chamber, then dorsal skin tissue was obtained, one part 
was used for histological analysis and the rest was used 
to prepare epidermal homogenates.  
In order to prepare epidermal homogenates total dorsal 
skin was immersed 30 s in water at 60 ˚C, then the epi- 
dermis was scraped from the dermis using a blade and 
homogenized in 2 ml of PBS, with 0.5 mg/ml EDTA and 
0.174 µg/ml PMSF (Sigma Chemical Co) in a glass ho- 
mogenizer with Teflon pestle, then centrifuged at 4˚C for 
15 min at 12,000 rpm. Afterwards, total protein concen- 
tration in the supernatant was measured with the BCA 
Protein Assay kit (Pierce), using bovine serum albumin 
(BSA) as standard. Finally, the epidermal extracts were 
stored at −70˚C until the assays were done.  
Cytokine quantification was performed by ELISA. 
Mouse TNF-α (epidermis extracts) was quantified using 
a non-competitive ELISA assay (BD Biosciences, San 
José, CA, USA), values were expressed as pg/mg of pro- 
tein. All assays were repeated at least three times.  
Skin samples for histological analysis were fixed with 
4% neutral formalin, and embedded in white paraffin. 
Samples were cut in 3 µm sections and stained with he- 
matoxylin-eosin (H-E). 
2.6. Data and Statistical Analysis 
Flow cytometric data was analyzed using Cyflogic soft- 
ware (version 1.2.1, CyFlo ltd, Turku, Finland). Graphi- 
cal and statistical analyses were performed with Graph- 
Pad Prism 5.0 (GraphPad Software Inc., San Diego, CA, 
USA). For the in vitro model Analysis of Variance 
(ANOVA) followed by a Dunnet postest was performed 
to make multiple comparisons against a control value and 
a Student’s t-test to compare means of two groups. For 
the in vivo model ANOVA followed by a Dunnet postest 
was performed in case of homoscedasticity and Kruskal- 
Wallis (non parametric ANOVA) followed by a Dunn 
postest in case of heteroscedasticity. Results are ex- 
pressed as mean ± SD; asterisks indicate significant at *p 
< 0.05, **p < 0.01, ***p < 0.001. 
3. Results 
3.1. Patients 
The study group consisted of 10 patients selected from a 
larger previous study; Table 1 shows their clinical cha- 
racteristics and laboratory findings. There were 4 patients 
with CP (2 SLE and 2 sSS, and 6 patients without CP (1 
SLE, 2 pSS and 3 sSS). Sjögren’s Syndrome was found 
secondary to SLE or RA. All patients had anti-Ro52 and 
anti-Ro60 appropriate titers; except one (p4) which did 
not present reactivity for Ro60. The average disease 
evolution among all 10 patients was of 5 years and their 
median age was 48.5 years old (between 24 and 83 years 
old), with 90% being female. 
3.2. Affinity Purification of Aabs against  
Recombinant Ro/SS-A 52 and Ro/SS-A 60  
kDa 
Anti-Ro52 Aabs were purified from 2 ml of serum using 
an affinity column with Ro52 protein coupled and an- 
ti-Ro60 Aabs were purified from another 2 ml of serum 
using an affinity column with Ro60 coupled. Subsequent  
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Table 1. Clinical and laboratory features of the 10 patients under study. SAP: systemic autoimmune pathology, CP: cuta- 
neous photosensitivity. Purified Aabs titer correspond to pH 3.5 pool, which was used for subsequent studies. 
 
Titer (log dil) 
Serum Purified Aabs 
Patient num SAP CP anti-Ro52 anti-Ro60 anti-Ro52 anti-Ro60 
1 SLE yes 4.41 3.20 2.51 1.51 
2 SLE yes 4.11 3.81 2.20 2.11 
3 sSS (SLE) yes 2.30 2.60 1.00 1.20 
4 sSS (SLE) yes 3.20 - 1.90 - 
5 sSS (SLE) no 3.81 4.11 2.51 2.20 
6 sSS (RA) no 5.61 2.90 4.01 1.81 
7 sSS (RA) no 4.71 4.41 3.71 2.71 
8 pSS no 4.41 3.81 2.81 2.11 
9 pSS no 4.00 3.51 2.30 1.90 
10 SLE no 4.11 3.20 2.20 1.81 
 
figures show patient num 6 (p6) as an illustrative exam- 
ple. 
Figure 1(a) shows the purification profile of p6 serum, 
where the reactivity by ELISA of each eluted fraction 
can be seen. The efficiency of the purification procedure 
was evaluated by titration of the serum by ELISA, before 
and after the affinity-purification procedure. Figure 1(b) 
shows the titration sigmoidal curves and titers of p6 se- 
rum, which needed to be re-purified in order to obtain the 
majority of the anti-Ro52 Aabs present in the serum, but 
purified only once for anti-Ro60 Aabs. Several sera 
needed a second purification procedure; and high reac- 
tivity fractions from both chromatographies of each se- 
rum were afterwards pooled. The criteria used to decide 
if a serum sample did not need to be re-purified was 
reaching a titer ≤2.3 (1/200 dilution) or a decrease in the 
titer ≥4 dilutions with respects to the original sample. 
For each patient, one pool was made from high reac- 
tivity fractions eluted at pH 3.5 and another pool from 
the ones at pH 2.7. Figure 1(c) shows the corresponding 
titers of the pooled fractions, none of them presented 
cross-reactivity against the other protein (e.g. anti-Ro52 
pH 3.5 pool did not exhibit reactivity against Ro60— 
Data not shown). Dialyzed pooled pH 3.5 fractions lost 
some anti-Ro reactivity with respects to the correspond- 
ing serum, but all of them retained enough reactivity in 
order to be used afterwards. Dialyzed pooled pH 2.7 
fractions lost almost all of their anti-Ro reactivity, so 
these fractions were not used afterwards. This reactivity 
decrease could be due to damage of the Aabs because of 
both low pH and manipulation, and also to sample dilu-  
tion. Titers of all sera and the corresponding purified 
Aabs (pH 3.5 pool) can be observed in Table 1. It is 
worth noticing that p6 is a special case for anti-Ro52, it 
has a significant high titer of those Aabs and it is the only 
patient whose pooled dialyzed pH 2.7 fractions retained 
an adequate reactivity, as it can be seen in Figure 1(c). 
For all the other 9 patients the situation is similar to what 
happens with dialyzed pH 2.7 fractions of anti-Ro60 
from p6. 
To confirm that purified Aabs were able to recognize 
the native antigen present in the cells, samples were 
tested by indirect immunofluorescence on Hep-2 cells. 
This is shown in Figure 2 for p6 as representative of the 
whole cohort, where it can be seen that the three samples 
were able to bind to the cells, presenting the typical 
speckled anti-Ro pattern. This was tested for all patients’ 
sera and their corresponding purified Aabs, confirming 
their ability to recognize the native antigen. Controls 
(NHS, hIgG and UBC) are also shown, with no positive 
images, as expected. 
3.3. In Vitro Model 
In a previous study on HaCaT cells we have determined 
that irradiation with 50 mJ/cm2 of UVB and evaluation of 
the cells 24 h post irradiation are the best conditions 
which produce the highest percentage of apoptotic cells 
with the lowest amount of living or necrotic ones [37]. 
Aabs binding to apoptotic keratinocyte’s cell surface was 
evaluated by flow cytometry for the serum of each pa- 
tient and the corresponding purified anti-Ro52 and anti- 
Ro60 Aabs. Figure 3(a) shows histograms with the  
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Figure 1. Affinity purification of autoantibodies (a) Profile 
of human anti-Ro52 and anti-Ro60 purified Aabs. Washing 
and elution, 1: PBS; 2: PBS-NaCl 0.5M; 3: Gly 0.1M pH 3.5; 
4: Gly 0.1M pH 2.7. (b) Anti-Ro52 and anti-Ro60 serum 
titration (sigmoidal curves) and serum titers (column bar 
graph) before and after the affinity-purification procedure. 
■: before purification; ▲: after purification; ●: after re- 
purification (only for anti-Ro52). (c) Anti-Ro52 and an- 
ti-Ro60 titers of A: serum; B: purified Aabs (pH 3.5 pool); 
C: purified Aabs (pH 2.7 pool). In all graphs: reactivity 
determined by ELISA measuring OD at 490 nm. Dotted line: 
cut off. All sera and purified Aabs from p6. 
 
marker used to select the FITC-positive cells. As p6 se- 
rum was the one with the highest anti-Ro52 titer, and 
showed a very high fluorescence when incubated with 
irradiated cells (Irr), it was used in all experiments as a  
 
Figure 2. Indirect immunofluorescence on Hep-2 cells. Sera 
and purified Aabs from p6 (anti-Ro52 and anti-Ro60) and 
controls (NHS, hIgG and UBC—unspecific binding control) 
are shown. 
 
 
Figure 3. Aabs binding capacity to apoptotic keratinocyte’s 
cell surface by flow cytometry. Histograms showing the 
number of events vs. FITC signal (FL1) correspond to (a) 
p6 samples: serum, purified anti-Ro52 Aabs and purified 
anti-Ro60 Aabs (b) controls: NHS, hIgG and UBC. Solid 
grey: samples on non-irradiated cells. Red: samples on ir- 
radiated cells. Marker: FITC positive cells. 
 
positive control in order to set the FITC-positive cells 
marker and to standardize subsequent data processing. 
Figure 3(b) shows the histograms corresponding to con- 
trols: NHS, hIgG and UBC on irradiated as well as on 
non-irradiated cells (nIrr). Figure 4(a) shows the binding 
capacity to apoptotic keratinocyte’s cell surface of all 10 
(a)
(b)
(c)
(a) (b)
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serum samples, expressed as Binding Index (BI) in arbi- 
trary units. This BI was used to standardize variations 
between experiments and was calculated as follows; con- 
sidering the mean fluorescence intensity (MFI) and the 
percentage of cells (%) under the selection marker: 
( ) ( )Score % MFI Irr cells % MFI nIrr cells= × − ×  
Score patient XBI
Score P6
=  
Figures 4(b) and (c) show the BI of anti-Ro52 puri- 
fied Aabs and anti-Ro60 respectively, for the 10 patients 
under study. BI for control NHS and hIgG were included 
in the graphs as a cut off; they were calculated as the 
mean of the BI of 5 independent experiments. These ex- 
periments prove that serum samples of the 10 patients did 
bind to keratinocytes’ cell surface, showing BI which 
were statistically significant greater than the BI for con- 
trol NHS. Their corresponding purified anti-Ro Aabs 
were also able to bind to the irradiated cells, both anti- 
Ro52 and anti-Ro60, most of them having a BI statisti- 
cally significant different from the BI for control hIgG. 
When patients were grouped according to the presence or 
absence of CP (Figure 4, lower row), there were no dif-
ferences found in the mean BI from the two groups. 
3.4. In Vivo Model 
Immunized SKH-1 Hairless mice were tested for serum  
reactivity against recombinant human Ro proteins and 
also against mice spleen extract in order to test autoreac- 
tivity, by ELISA. By the end of the immunization sche- 
dule all animals from groups 1, 2 and 3 were able to react 
against both types of proteins (Figure 5), in a statistically 
significant different way compared to group 4 (control).  
Mice with circulating anti-Ro Aabs were divided in 
two groups, one was irradiated and the other mocked- 
irradiated (on day 144 of the immunization schedule). 
They were sacrificed 24 h later and histological analysis 
and cytokine quantification were performed. Figure 6 
shows the skin sections of one representative mouse from 
each group of animals, where it can be seen that there 
were no differences between immunized non irradiated 
groups and the corresponding irradiated ones, except for 
the known effects of UVB irradiation on the skin [36,39]. 
Only one group showed a slight difference with respects 
to the others: when irradiated, group 1 presented a slight 
inflammatory infiltrate not seen in the other groups. 
TNF-α production quantified in epidermal extracts can 
be seen in Figure 7. It is observed that TNF-α is barely 
not detectable in non irradiated mice, while its levels 
increased in all irradiated animals as expected, but 
showing no statistically significant differences between 
groups. 
4. Discussion 
In the present study a group of 10 Argentinean middle  
 
 
Figure 4. Binding Index (BI) to apoptotic keratinocyte’s cell surface of all ten patients, expressed as arbitrary units. (a) Se-
rum samples (b) Anti-Ro52 purified Aabs (c) Anti-Ro60 purified Aabs. BI for control NHS and hIgG were included as cut off 
(mean ± 2SD). Patients were grouped according to the presence (CP) or absence of CP (noCP) and their diagnosed disease is 
also shown. Upper Row: BI for each patient and each of their corresponding samples. Samples statistically different from 
control (p < 0.05) are indicated with an asterisk (*), ANOVA followed by a Dunnet postest was used. Lower Row: mean BI for 
each patient. The exact p value is indicated, obtained by a Student’s t-test. 
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Figure 5. Mice serum reactivity by ELISA at day 120 of the immunization schedule. The three groups of immunized mice 
were tested against (a) Recombinant human Ro52 (b) Recombinant human Ro60 (c) Mice spleen extract. ANOVA or 
Kruskal-Wallis were performed, and samples statistically different from control group are indicated with an asterisk (*p < 
0.05, **p < 0.01, ***p < 0.001). 
 
 
Figure 6. H-E skin sections of one representative mouse 
from each group of animals. Left: immunized (or control) 
non irradiated groups. Right: immunized (or control) irra- 
diated groups. 
 
aged patients was studied. They were selected from a 
cohort of 169 individuals, attempting to compose two 
homogeneous groups: one group consisting of patients 
with CP and the other one of patients without CP. All of 
them with high anti-Ro52 and/or anti-Ro60 titers, and  
 
Figure 7. TNF-α quantification in epidermal extracts. White 
bars: immunized (or control) non irradiated groups. Grey 
bars: immunized (or control) irradiated groups. Kruskal- 
Wallis (non parametric ANOVA) followed by a Dunn post- 
test was performed, differences between immunized irra- 
diated groups were not significant. 
 
with the same kind of SAP: SLE or SS. Purification of 
anti-Ro52 and anti-Ro60 individually from each patient’s 
serum was feasible, some of them needed to be re-puri- 
fied, and all the Aabs pure pooled fractions exhibited 
reactivity against recombinant and also native antigens, 
and a titer which was adequate to use in subsequent ex- 
periments and suitable to make comparisons with the 
corresponding serum. 
HaCaT cells were irradiated with 50 mJ/cm2 of UVB 
light and labeled for flow cytometry 24 h after, in this 
way high levels of apoptotic cells were obtained, as it has 
been previously described by us [37]. Therefore, UVB 
irradiated cells are a good in vitro model to test binding 
of Aabs to cell surfaced relocalized autoantigens. Bind- 
ing capacity to apoptotic keratinocyte’s cell surface was 
expressed as BI to standardize the results, and NHS and 
hIgG were used as control of basal normal binding, and 
they were set as a binding cut off. The entire set of sera 
and Aabs were tested on non-irradiated cells, exhibiting 
no binding to these living cells. When cells were UVB- 
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irradiated they underwent apoptosis, relocalizing the au- 
toantigens, therefore sera of the 10 patients were able to 
bind to the keratinocyte’s cell surface, showing greater 
BI values than NHS. NHS and hIgG on irradiated cells 
showed higher fluorescence intensity compared to values 
on non-irradiated cells, this could be explained since it 
has been proven that Ro52 autoantigen is capable of 
binding human IgG1 nonspecifically through its heavy 
chain [40,41]. It can be concluded that serum of the 10 
patients did bind to apoptotic keratinocytes, as well as 
their corresponding purified anti-Ro Aabs. All anti-Ro52 
and anti-Ro60 purified Aabs but one show BI values 
greater than control ones, though due to a difference in 
the IgG mass between purified Aabs and control hIgG 
some values did not reach statistical significance. It can 
also be seen that there is no relationship between the sera 
binding capacity and the presence or absence of CP, not 
either with the SAPs. We are aware that 10 patients is not 
a significantly elevated number, nevertheless, we believe 
that the conclusions obtained are legitimate, not only 
because they are coherent among themselves, but also 
because they are in agreement with other studies.  
These results are in agreement with our recent study 
on 169 patients’ sera [24] of the direct relationship be- 
tween the occurrence of CP and the presence of certain 
Aabs. We found that there was no association between 
the presence of anti-Ro Aabs and the occurrence of CP. 
This was true for anti-Ro52 as well as for anti-Ro60, 
both for presence and titer. Besides our results, there are 
many other reports where no direct relationship was 
found between clinical photosensitivity and the presence 
of anti-Ro Aabs, such as studies in Japanese, black South 
African SLE patients and others [22,42,43]. Taking into 
account that anti-Ro Aabs are not a sine qua non of pho- 
tosensitivity because 1) they are not commonly found in 
association with DLE, though DLE patients do present 
CP 2) healthy people can manifest CP without anti-Ro 
Aabs 3) there is the above-mentioned case of pSS pa- 
tients which do have high titer of anti-Ro circulating 
Aabs, but do not show signs of CP, it is reasonable to 
think that anti-Ro Aabs are not necessarily the causative 
or the only responsible of causing CP.    
However, there are many studies that indicate a posi- 
tive relationship between anti-Ro Aabs and CP, like the 
ones which measure the binding of sera containing anti- 
Ro Aabs from patients to self-derived irradiated kerati- 
nocytes [18-20]. These studies were always performed 
with sera which were tested by various techniques to be 
only specific for one autoantigen, among 4 or 5 different 
ones. The usage of this kind of monoespecific sera has 
many disadvantages, like 1) not being completely repre- 
sentative of a SAP’s patient 2) having the monoespeci- 
ficity tested against only a few well-known autoantigens  
and 3) the usage of serum instead of pure Aabs, implying 
that other antibodies (not tested in the “monoespecificity 
assay”) could be present in those monoespecific sera and 
interacting with the irradiated keratinocytes. Those as- 
says were also performed on patients’ own keratinocytes, 
and it has been shown that keratinocytes from cutaneous 
LE patients showed a higher susceptibility to a single- 
dose UVB light irradiation compared to keratinocytes 
from normal controls, and that the binding of Aabs was 
more up-regulated when cultured keratinocytes were 
reacted with autologous sera [29]. Anyhow, experiments 
were always performed using sera and we suggest that, 
according to our results, there might be other Aabs im- 
plicated in the pathogenesis of CP that are not essentially 
anti-Ro Aabs, and that those Aabs could be the anti-Sm 
ones, due to the fact that we—and also other authors— 
[24,27,43] have previously found a statistically signifi- 
cant direct positive association between CP and high 
reactivity anti-Sm Aabs.  
We have used an in vivo model to also test the rela- 
tionship between anti-Ro Aabs and CP. Since there is 
similarity between the sequence of the human and mice 
Ro proteins [44,45], and also there is spreading of mice 
immune response towards an autoimmune profile [46,47], 
then we succeed in generating Aabs against murine Ro52 
and/or Ro60 autoantigens in the immunized mice. Mice 
with circulating anti-Ro Aabs were divided in 2 groups, 
one was irradiated and the other mocked-irradiated. 
TNF-α production showed no statistical differences be- 
tween the 3 immunized-irradiated groups and the non 
immunized-irradiated control group; neither did the eva- 
luated parameters by histological analysis, except for the 
slight inflammatory infiltrate found in the irradiated 
group immunized with Ro52. This fact suggests that the 
single presence of anti-Ro Aabs is not the only require- 
ment for the development of CP, and many other media- 
tors might be involved in the pathogenesis of the manife- 
station. 
5. Conclusion 
To sum up, using the two approaches studied in the 
present work, it can be concluded that anti-Ro Aabs are 
not related to the CP phenomenon, or at least, they are 
not the only responsible for the CP pathogenesis. These 
results agree with some studies on the role of the Aabs in 
CP, considering anti-Ro Aabs not as the only ones in-
volved in the manifestation; and disagrees with many 
other authors, who believe in the strong association be- 
tween these two events. Nonetheless, many issues remain 
to be investigated and solved before any definite conclu- 
sion can be drawn about the pathogenesis of photosensi- 
tivity. 
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